9 Meters Biopharma Inc
OTC:NMTRQ

Watchlist Manager
9 Meters Biopharma Inc Logo
9 Meters Biopharma Inc
OTC:NMTRQ
Watchlist
Price: 0.0001 USD
Market Cap: 1.4k USD

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
9 Meters Biopharma Inc
OTC:NMTRQ
1.4k USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
977.5B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
519.4B USD
Loading...
CH
Roche Holding AG
SIX:ROG
272.5B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
206.5B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.3B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
144.7B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

9 Meters Biopharma Inc
Glance View

Market Cap
1.4k USD
Industry
Pharmaceuticals

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.

NMTRQ Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top